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Abstract
Background: Complex diseases are associated with altered interactions between thousands of genes. We
developed a novel method to identify and prioritize disease genes, which was generally applicable to complex
diseases.
Results: We identified modules of highly interconnected genes in disease-specific networks derived from
integrating gene-expression and protein interaction data. We examined if those modules were enriched for
disease-associated SNPs, and could be used to find novel genes for functional studies. First, we analyzed publicly
available gene expression microarray and genome-wide association study (GWAS) data from 13, highly diverse,
complex diseases. In each disease, highly interconnected genes formed modules, which were significantly enriched
for genes harboring disease-associated SNPs. To test if such modules could be used to find novel genes for
functional studies, we repeated the analyses using our own gene expression microarray and GWAS data from
seasonal allergic rhinitis. We identified a novel gene, FGF2, whose relevance was supported by functional studies
using combined small interfering RNA-mediated knock-down and gene expression microarrays. The modules in the
13 complex diseases analyzed here tended to overlap and were enriched for pathways related to oncological,
metabolic and inflammatory diseases. This suggested that this union of the modules would be associated with a
general increase in susceptibility for complex diseases. Indeed, we found that this union was enriched with GWAS
genes for 145 other complex diseases.
Conclusions: Modules of highly interconnected complex disease genes were enriched for disease-associated SNPs,
and could be used to find novel genes for functional studies.
Background
Medical research often focuses on individual diseases and
genes. However, complex diseases show considerable
comorbidity and are associated with altered interactions
between thousands of genes. This suggests a need to find
generally applicable principles to study multiple diseases
and genes. One solution may be to map differentially
expressed, disease-associated genes on to the human pro-
tein-protein interaction (PPI) network. Gene expression
microarray studies of several complex diseases have shown
that differentially expressed genes tend to form modules
of interacting and functionally related genes [1-5]. Those
modules may help to identify genes harboring disease-
associated SNPs [6]. The identification is, however, com-
plicated by the involvement of multiple modules in the
same complex disease.
In this study, we hypothesized that modules containing
the most interconnected complex disease-associated
genes would be enriched for disease-associated SNPs
(note that highly interconnected disease genes have many
interactions with other disease genes, while hub genes
have interactions with any other gene). This hypothesis
was based on recent discoveries in network medicine.
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Firstly, the effects of disease-associated SNPs tend to pro-
pagate through the PPI network, affecting the local
neighborhood around the SNP-harboring genes [7-9].
Secondly, genes harboring disease-associated SNPs tend
to form modules in the PPI network [10-13]. Those stu-
dies are mainly based on rare hereditary diseases. A
recent meta-analysis of genome-wide association studies
(GWAS), however, suggests that genes harboring disease-
associated SNPs in complex diseases are also highly inter-
connected [14]. Taken together, previous studies showed
that genes harboring disease-associated SNPs tend to
form modules, and that the same is true for differentially
expressed genes [15]. In this study, we integrated these
two findings and used modules formed by differentially
expressed disease genes to find genes harboring disease-
associated SNPs. For this, first we defined modules in dis-
ease-specific networks for 13 complex diseases and show
that these highly interconnected genes in these modules
are enriched for disease genes identified through GWAS.
To test the general applicability of our findings, the
selected diseases were highly diverse and included onco-
logical, metabolic and inflammatory diseases. Using in-
house generated gene-expression and GWAS data, we
showed that such modules could be used for identifying
novel genes for functional studies, using seasonal allergic
rhinitis (SAR) as a disease model. Finally, we show that
overlapping modules of the complex diseases are gener-
ally enriched for genes harboring disease-associated
SNPs, especially pleiotropic genes, identified by GWAS
of 145 complex diseases.
Results
Disease-specific core susceptibility modules are enriched
for disease-associated genes in 13 complex diseases
We defined modules in disease-specific networks by
using (a) the global human PPI network and (b) differen-
tially expressed genes for each disease. Those modules
will henceforth be referred to as susceptibility modules
(SuMs). Genes with high interconnectivity in the SuMs
were defined as core SuMs (Figure 1; see Materials and
methods). We examined whether the disease-specific
core SuMs were enriched for genes harboring disease-
associated SNPs by analyzing complex diseases for which
gene expression microarray data from relevant cells or
tissues were available in the public domain, and where
GWAS had identified genes harboring disease-associated
SNPs. Such genes will henceforth be referred to as
GWAS genes. Thirteen oncological, immunological or
metabolic diseases fulfilled these criteria (Table 1; Addi-
tional file 1). For each disease, we derived a SuM and
within it, a core SuM. The enrichment of GWAS genes
in the core SuMs was 4.71-fold compared to the whole
PPI network (P < 10-5). The corresponding figure of the
SuMs was 2.22-fold (P < 10-5). In contrast, using only
differentially expressed genes we found a mere 1.15-fold
enrichment of GWAS genes (P = 0.3; Figure 2a). We
tested different cutoffs for interconnectivity. We found
that increasingly stringent cutoffs for core SuMs were
associated with stronger enrichment of GWAS genes
(Figure 2b). Based on these analyses we defined core
SuMs as the 10% of the SuM genes with the lowest aver-
age shortest path length. This demonstrated the effective-
ness of modules to identify GWAS genes, compared to
differentially expressed genes.
Core SuMs could be used to find novel genes for
functional studies
We then determined whether core SuMs could be used
to find novel genes for functional studies. We repeated
the analyses using our own gene expression microarray
and GWAS data from patients with SAR. This is an ideal
model of complex diseases because it is possible to
mimic and analyze the disease process in allergen-chal-
lenged cells from patients [16] (Extended background in
Additional file 2). Novel genes can be functionally exam-
ined by combining small interfering RNA (siRNA) and
gene expression microarrays in Th2 polarized cells
[17-19], (Extended background in Additional file 2).
We constructed a SuM and a core SuM for SAR using
differentially expressed genes obtained by performing
gene expression microarray analysis of allergen-chal-
lenged CD4+ cells in samples from 12 patients as pre-
viously described [19,20] (Additional file 3). The SuM
included 622 of the 2,822 differentially expressed genes
in the PPI network, and 1,191 genes in total (Figure 1a in
Additional file 4). Next, we tested if they could be repli-
cated in the additional study material. The repeated ana-
lyses resulted in highly similar SuMs and core SuMs (P <
10-15 in both cases, determined by a c2-test; Figure 1b in
Additional file 4). We also compared gene expression
microarray data from allergen-challenged CD4+ cells
from patients with SAR and allergen-challenged CD4+
cells from healthy controls and found differences in dis-
ease-relevant pathways and genes (Extended results in
Additional file 2).
To determine whether the genes in the SuM and core
SuM were enriched for SAR-associated SNPs, we analyzed
an independent GWAS of 4,772 individuals in the North
Finland Birth Cohort (Figure 1e). We found that intragenic
SNPs within the 119 genes in the core SuM were 3.4 times
more likely to be disease-associated than expected by
chance (P = 1 × 10-5). This led to the identification of two
novel genes, FGF2 and MAPK8 (Additional file 5). These
findings were appropriately supported by false discovery
rate calculations (Extended results in Additional file 2;
Additional file 6). These genes had not been previously
associated with SAR [21]. While MAPK8 has a known role
in type 1 allergic inflammation [22-24], FGF2 is a novel
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gene. We tested the functional relevance of FGF2 by
siRNA-mediated knock-down of this gene in Th2 polar-
ized cells, followed by gene expression microarrays
(Extended methods and Extended results in Additional file
2; Additional file 7). The knock-down resulted in altered
expression of several pathways of potential relevance for
type 1 allergic inflammation, as well as individual genes of
known relevance for type 1 allergic inflammation, includ-
ing MAFB and NFKB1 [25-30] (Additional file 8). In con-
trast to the core SuM, no enrichment of SNPs was found
in the SuM.
The union of core SuMs of different diseases was
enriched for pleiotropic genes
Because complex diseases tend to show both phenotypic
and genotypic overlap [31,32], we hypothesized that the
core SuMs would be associated with generally increased
susceptibility for all complex diseases. In support of this
assertion, we found that the core SuMs from the 13 dis-
eases tended to overlap. This tendency was stronger for
core SuMs than SuMs (Figure 3a). The union of the
core SuMs was highly enriched for pathways involved in
oncological, metabolic and inflammatory complex
(a)
(b)
(c)
Maximal
cliques
Human 
protein-protein 
interaction 
network
Cliques
enriched for
differentially
expressed
genes
Overlapping 
cliques form 
the Suceptibility
Module (SuM)
The most 
interconnected 
genes form 
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(d)
(e) Enrichment of 
GWAS genes 
in core SuM
Figure 1 Overview of identification of susceptibility modules (SuMs). (a) Maximal cliques were obtained from a human PPI. (b) Disease-
associated cliques were identified by selecting those that were enriched for differentially expressed genes. (c) Such cliques were mapped onto
the PPI network, resulting in the identification of a SuM of overlapping cliques. (d) A core SuM was identified using average shortest path
length. (e) This core SuM was validated by showing enrichment for GWAS genes.
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diseases (Additional file 9). Finally, we tested whether
the union of the core SuMs was generally enriched for
GWAS genes of various complex diseases. This test
comprised 1,570 GWAS genes associated with 145 com-
plex diseases, excluding the genes associated with the 13
complex diseases for which the core SuMs were derived
(Additional file 1). We found 2.52-fold enrichment
compared to the whole PPI network (P < 10-18). The
enrichment increased if the disease genes were pleiotro-
pic, that is, associated with more than one disease (Fig-
ure 3b). For example, when considering only genes
associated with more than one disease, we found a 3.1-
fold enrichment (P < 10-6), and when considering genes
only associated with more than four diseases we found a
9.1-fold enrichment (P < 10-3).
Discussion
We have developed a novel method to define SuMs and
core SuMs for complex diseases by combining gene-
expression microarray and PPI data. To show the gen-
eral applicability of the method, we analyzed diseases
with highly divergent phenotypes, rather than focusing
on a specific subset of phenotypically related diseases.
We found that SuMs, and in particular core SuMs, were
enriched for GWAS genes. By comparison, no enrich-
ment of GWAS genes was found when analyzing all dif-
ferentially expressed genes.
To test if core SuMs could be used to find novel
genes for functional studies, we analyzed our own gene
expression microarray and GWAS data from patients
with SAR. This is an optimal model of complex diseases
in that it has a clearly defined phenotype that occurs at
a given time point each year and the external cause
(pollen) and key cell-type (lymphocytes) are known
(Extended background in Additional file 2). We identi-
fied a SuM and a core SuM, which were reproduced in
an independent study. We tested for enrichment of
GWAS genes by analyzing a large population-based
GWAS. This led to the identification of two novel genes
in the core SuM. One of those genes, FGF2, was novel
in type 1 allergic inflammation. The relevance of this
Table 1 Overview of SuMs in 13 complex diseases
GWAS genes in PPI GWAS genes in SuM GWAS genes in core SuM
Disease GEO accession Genes in SuM network Observed Expected Observed Expected
Asthma GSE4302 587 8 1 0.39 0 0.04
Breast cancer GSE10810 2,474 7 2 1.45 1 0.15
Chronic lymphocytic leukemia GSE8835 1,787 11 3 1.64 0 0.17
Colorectal cancer GSE9348 1,651 5 3 0.69 1 0.07
Crohn’s disease GSE6731 1,458 16 5 1.95 3 0.20
Lung adenocarcinoma GSE7670 2,524 10 4 2.11 0 0.21
Obesity GSE12050 2,268 13 4 2.47 0 0.25
Parkinson’s disease GSE20141 1,871 21 5 3.29 1 0.33
Prostate cancer GSE6919 751 16 3 1.01 1 0.10
Psoriasis GSE13355 2,274 12 8 2.28 1 0.23
Schizophrenia GSE17612 1,586 18 4 2.39 0 0.24
Type 2 diabetes GSE20966 1,658 21 5 2.91 2 0.29
Ulcerative colitis GSE6731 2,365 25 13 4.95 3 0.50
Total - - - 60 27.53 13 2.76
Gene expression dataset for each disease obtained from the NCBI Gene Expression Omnibus (GEO).
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Figure 2 Enrichment of GWAS genes from 13 oncological,
immunological and metabolic diseases in SuMs and core SuMs.
(a) The enrichment of GWAS genes in core SuMs was stronger
when the cutoff was more restrictive. The 10% cutoff was chosen to
define core SuMs. (b) SuMs and core SuMs show strong enrichment
of GWAS genes compared to differentially expressed (DE) genes.
Error bars represent the 95% confidence interval of the randomized
selections. Asterisks represent p < 0.001.
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gene was supported by transcriptomal analysis following
siRNA-mediated knock-down. The knock-down of FGF2
resulted in altered expression of pathways and genes of
potential or known relevance for type 1 allergic inflam-
mation. In contrast, we found no enrichment of GWAS
genes among all differentially expressed genes. These
findings support the hypothesis that core SuMs can be
used to identify GWAS genes with moderate effect sizes
as well as novel genes for functional studies.
Studies of complex diseases often focus only on specific
diseases and the genes associated with them. However,
complex diseases show considerable phenotypic and gen-
otypic overlap. Moreover, the effects of individual com-
plex disease genes are generally small, while their
collective contribution may be large [33]. This has led to
increasing interest in studying groups of diseases and
genes [31,32,34,35]. In the final part of our study, we
made a corresponding change of scale and considered
whether core SuMs from the 13 studied diseases were
associated with an increased susceptibility for complex
diseases, in general. We found that core SuMs tended to
overlap, suggesting that they were involved in shared
pathogenic mechanisms in complex diseases. This was
supported by the union of the core SuMs being enriched
for pathways involved in complex diseases. Finally, we
tested if the union of the core SuMs was generally
enriched for GWAS genes from 145 complex diseases,
which represented hundreds of thousands of patients.
Indeed, that union was highly enriched for such GWAS
genes. Interestingly, the enrichment was greater when
considering only GWAS genes associated with more than
one disease. Taken together, our findings showed that
the core SuMs of highly interconnected disease genes
were associated with increased susceptibility for complex
diseases.
We propose that the pathways in the core SuMs
increase our understanding of how shared pathogenic
mechanisms contribute to complex diseases, and also
help explain why many of those diseases show phenoty-
pic overlap [36]. From a therapeutic perspective, the core
SuMs may be used to prioritize therapeutic novel genes.
It should, however, be noted that even though the num-
ber of genes in the core SuMs was considerably smaller
than all the differentially expressed genes, it may be diffi-
cult to find individual target genes. Instead, perhaps
drugs targeting combinations of core SuM genes will be
required. Another interesting possibility is that the same
novel genes might be exploited to develop drugs that tar-
get more than one disease. From a diagnostic perspective,
different combinations of SuM and core SuM proteins
may be useful as diagnostic markers. We propose that
such studies can be performed in both specific disease
groups and diseases.
A limitation of this study is that it is mainly based on
GWAS genes reported in a public database. This may
result in missing GWAS genes in some core SuMs, due
to too stringent cutoffs. In this study, we analyzed only
intragenic SNPs, while intergenic SNPs may have regula-
tory and disease-causing roles. Another limitation is that
the study is based on known physical and functional
PPIs. Thus, our results may be confounded by knowledge
bias. Moreover, some of the gene expression microarray
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Figure 3 Similarity of core SuMs of different diseases and enrichment of disease genes in the union of core SuMs. (a) Heatmap
showing that core SuMs are more similar than SuMs. The color intensity represents similarity, defined by computing the ratio between the
number of genes shared by two SuMs and the total number of genes in the two SuMs (Jaccard similarity index). (b) In an extended analysis of
GWAS genes of 145 other diseases, the union of the core SuMs was enriched with GWAS genes. This enrichment increased with disease gene
pleiotropy. CLL,.
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studies used in this effort were performed in tissues that
contained mixed cell populations. We anticipate that the
increasing accuracy of PPIs as well as availability of gene
expression microarray and GWAS data will lead to more
accurate identification of SuMs.
Conclusions
SuMs and core SuMs may be used to find novel genes
for functional studies, as well as to increase understand-
ing of the specific and shared pathogenic mechanisms in
complex diseases and how they relate to phenotypic
manifestations.
Materials and methods
Definition of susceptibility modules of complex diseases
SuMs were defined by integrating PPI network data and
differentially expressed genes for each disease. The PPI
network was assembled from a large set of functional
and physical PPIs obtained from STRING (version 8,
using interactions with a confidence score ≥ 0.7). The
SuMs were identified using a step-wise process. First,
maximal cliques were extracted from the PPI network
(A clique is a complete sub-network, that is, a sub-net-
work with links connecting every pair of its nodes (Fig-
ure 1a) [37]. Such a clique is maximal if it is not
properly contained within another clique.) For this task
we employed our custom clique extraction tools as pre-
viously applied [38,39]. We noted that maximal cliques
tend to be highly overlapping and we used all cliques
down to a minimum size of 2 that were not part of
other cliques. Each clique was tested for enrichment (P
< 0.05) of differentially expressed genes in the disease
using Fisher’s exact test (Figure 1b). Differentially
expressed genes between the patient and control sam-
ples were determined using a Student’s t-test with a P <
0.05. Finally, overlapping enriched modules/cliques were
mapped onto the PPI network so that each gene was
represented only once, and overlapping enriched cliques
could be identified as SuMs (Figure 1c). The SuMs
included both differentially expressed genes and their
neighbors in these cliques. In the SuMs, we identified
highly interconnected genes and defined them as core
SuMs (Figure 1d). Interconnectivity was measured by
calculating the average shortest path length using the
Network-Analyzer (v2.6.1) plug-in in Cytoscape (v2.6.0).
Enrichment of core SuMs for GWAS genes
GWAS genes for all complex diseases were obtained
from ‘a catalog of published Genome-wide association
studies’ [40]. We tested for enrichment of GWAS genes
using a permutation test. In each permutation, every
GWAS gene was replaced with a random gene. The
number of random genes present in the corresponding
SuMs or core SuMs was noted. This process was
repeated 100,000 times. The total number of random
genes present in the disease SuMs represented the prob-
ability of finding GWAS genes in the SuMs by chance.
The significance of the overrepresentation of GWAS-
identified genes in the SuMs was measured as the ratio
of random permutations that included as many or more
SuM genes than the true GWAS-identified genes for all
13 diseases. Similarly, enrichment of GWAS genes in
the union of core SuMs was also determined for 145
diseases. Pathway enrichment for the union of core SuM
genes was determined using Ingenuity Pathway Analysis
[17].
Gene-expression microarray analysis in seasonal allergic
rhinitis
Peripheral blood mononuclear cells from patients with
SAR and healthy controls were prepared and stimulated
with grass pollen extract or diluent for seven days [20].
For gene expression studies, T helper cells were
enriched from the allergen-challenged peripheral blood
mononuclear cells using anti-CD4-coated paramagnetic
microbeads and a MACS (magnetic cell sorter) system
according to the instructions of the manufacturer (Mil-
tenyi Biotec GmbH, Bergisch Gladbach, Germany).
cRNA was extracted from 200 ng total RNA using
Ambion’s Illumina RNA TotalPrep Amplification kit
(Ambion, Inc., USA). In vitro transcription reaction and
cRNA biotinylation were performed overnight (14 h).
The RNA/cRNA concentrations where checked using
Nanodrop ND-1000 before and after the amplifications.
cRNA quality was controlled by BioRad’s Experion elec-
trophoresis station (Bio-Rad Laboratories, Inc., CA,
USA). Transcriptional profiling in 12 patients was per-
formed using Illumina’s Sentrix® Human-6 Expression
BeadChips (Illumina Inc., San Diego, CA, USA) accord-
ing to the manufacturer’s instructions. (The data can be
obtained from the Gene Expression Omnibus under
accession number GSE18574.) Probes with a detection
score below 0.95 were discarded prior to differential
expression analysis. Differentially expressed genes were
determined using lmFit from the Bioconductor package
Limma [41] (Additional file 3). Genes with a P-value <
0.05 after correction for multiple comparisons (false dis-
covery rate) were determined to be differentially
expressed. To validate results obtained from the data
above, an additional set of patients (n = 3) was analyzed
on an Affymetrix U133A platform as previously
described [20].
GWAS analysis for seasonal allergic rhinitis
This cohort (NFBC1966) included individuals from the
provinces of Oulu and Lapland [42]. In 1997 (when par-
ticipants were aged 31 years), 8,463 survivors were sent
postal questionnaires and invited to clinical examination
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with a 71% response rate. DNA was collected for the
majority of participants and a total of 4,772 individuals
were successfully genotyped. All aspects of the study
were reviewed and approved by the Ethics Committee
of the University of Oulu and participants gave written
informed consent. Genotyping was done using the Illu-
mina HumanCNV370-Duo chip. The data were imputed
to approximately 2.5 million SNPs using NCBI HapMap
II CEU build 35 version 21 after pre-filtering SNPs (gen-
otyping rate > 95%, P-value for HWE deviation > 10-4,
minor allele frequency > 1%, imputation with a confi-
dence call of R2 > 0.5) using IMPUTE [43].
The SAR phenotype was defined as a positive response
to the ‘have you ever had allergic rhinitis’ question in
the main questionnaire and a positive skin prick test for
grass. Controls had a negative response to the question
and a negative skin prick test. A positive skin prick test
was defined as a mean wheal reaction to grass extract of
at least 3 mm. Participants with a positive reaction to
negative control (diluent of allergen extracts) or a nega-
tive reaction to positive control (10 mg/ml histamine
dihydrochloride) were excluded. There were 456
patients that had SAR, while 2,569 individuals were
controls.
Association tests for additive effects between SNPs
and the defined phenotypes were conducted using the
QUICKTEST software and supplemented using R.
These analyses were adjusted for sex and relevant prin-
cipal components of population stratification. Statisti-
cally significant SNPs located within and outside the
genes of the core SuM were assessed. A SNP was
assigned to a gene if that SNP position lies within the
start and end region of the gene DNA sequence as
defined by the Ensembl database [44]. A higher propor-
tion of SNPs within the genes of the core SuM when
compared with the background level of association is
indicative of the relevance of the core SuM for the phe-
notype. The P-value of this test is the cumulative prob-
ability of finding k or more SNPs in that gene subset
when the probability of sampling k SNPs is given by the
hypergeometric distribution. The cutoff of the statistical
significance of SNP association was determined to be a
= 10-3 via sensitivity analysis of the P-values, false dis-
covery rate, true positive rate and odds ratio of the core
SuM enrichment (Additional file 6). The false discovery
rate was given by FDR = FP/P, where P is the number
of positive SNP associations and FP is the number of
false positive SNP associations within the core SuM
under the null hypothesis distribution:
FP =
∑m
x
p(x, k,m,n)x
where p(x, k, m, n)x is the P-value of the hypergeo-
metric distribution when x out of the k significant SNPs
are observed within the core SuM, when the core SuM
holds m of the total n SNPs. The number of true posi-
tive SNP associations (TP) is given by TP = P - FP. The
odds ratio of the enrichment was defined as the odds of
a significant SNP within the core SuM (or any given
subset of genes) as compared to the remaining genes.
The linkage disequilibrium within the core SuM is
assumed to be similar to the expected linkage disequili-
brium in the rest of the genome; therefore, GWAS P-
value distributions within and outside the core SuM
should be comparable.
Additional material
Additional file 1: Additional Table 1 - the genes associated with
each disease in the online GWAS catalogue (data obtained on 10
January 2012).
Additional file 2: Additional documentation providing Extended
background, Extended experimental methods and Extended results.
Additional file 3: Additional Table 2 - differential expression
analysis of allergen-challenged CD4+ cells compared to diluent-
challenged controls in SAR.
Additional file 4: Additional Figure 1 - the SuM associated with
seasonal allergic rhinitis.
Additional file 5: Additional Table 3 - all disease-associated SNPs in
the SAR SuM.
Additional file 6: Additional Figure 2 - sensitivity analysis of the
statistical significance level a of a SNP on the Core SuM
enrichment.
Additional file 7: Additional Table 4 - differentially expressed genes
in Th2 polarized cells following FGF2 knockdown.
Additional file 8: Additional Figure 3 - analysis of FGF2 by siRNA-
mediated knock-down of FGF2 in Th2 polarized cells, followed by
gene expression microarrays.
Additional file 9: Additional Table 5 - pathways enriched in the
combined set of core SuM genes.
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